路易称:“把所有数据集中到一起是一回事,能否有效利用它们却是另外一回事。必须能把生物信息学和对癌症及症状的深入了解结合起来才行。”
The large cancer institutes may have more limited data sets, given that they don’t aggregate data from a variety of sources the way Flatiron does, “but I’d argue the researchers there may be more aware of the subtleties of genomics and probably can analyze the data more effectively,” he said.
大型癌症研究机构可能数据量相对有限,因为它们没法像Flatiron那样从多种渠道收集数据,他说:“但我认为这些机构的研究人员可能更懂得深奥的基因组学,也可能更有效地分析数据。”
There are other EMR systems that Flatiron competes with, Turner says, such as Epic. But for analytics, “I honestly haven’t seen too many,” he said. “Maybe Microsoft Excel.”
特纳称,在电子病历系统上Flatiron公司也是有对手的,如Epic。但就这些病历的分析来说,他表示:“我还真没看到多少对手,也许微软公司(Microsoft)的Excel算一个。”
IBM is also a player, but “they’re very geared toward the top one percent and focused on decision support,” Turner said. The American Society of Clinical Oncology’s CancerLinQ is another.
IBM公司同样也是对手之一,但“它们主要致力于为1%的客户服务,并专攻决策支持,”特纳称。而美国临床肿瘤协会(American Society of Clinical Oncology)的CancerLinQ算另一个。
【科技是否万能 大数据能够战胜癌症吗】相关文章:
最新
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15